Table 4.
Compound | Generic/Brand | Dosing Strength | Route | Dosing Frequency | AWP Range* |
---|---|---|---|---|---|
Bisphosphonates | |||||
Alendronate | Generic | 5 mg, 10 mg | PO | Daily | $87.68–$87.80 |
35 mg, 70 mg | Weekly | $4.26–$82.52 | |||
Risedronate | Generic | 150 mg | PO | Monthly | $223.80–$318.58 |
5 mg | Daily | $265.67 | |||
35 mg | Weekly | $247.80–$247.81 | |||
Atelvia (Allergan) | 35 mg (DR) | Weekly | $304.93 | ||
Generic | 35 mg (DR) | Weekly | $209.21–$209.22 | ||
Ibandronate | Generic | 150 mg | PO | Monthly | $17.00–$168.40 |
1 mg/mL 3 mL vial |
IV | Every 3 months | $500.00–$505.20 (every 3 months) | ||
Boniva (Genentech) | 150 mg | PO | Monthly | $229.14 | |
Boniva (IV) (Genentech) | 1 mg/mL 3 mL vial |
IV | Every 3 months | $632.88 (every 3 months) | |
Zoledronic acid | Generic | 5 mg/mL 100 mL vial |
IV | Yearly | $270.00–$1,004.42 (per year) |
Reclast (Novartis) | 5 mg/mL 100 mL vial |
Yearly | $1,300.60 (per year) | ||
RANKL Inhibitor | |||||
Denosumab | Prolia (Amgen) | 60 mg/mL 1 mL syringe |
SC | Every 6 months | $1,353.84 (every 6 months) |
Estrogen Agonist/Antagonists | |||||
Raloxifene | Generic | 60 mg | PO | Daily | $192.22–$213.84 |
Evista (Eli Lilly) | 60 mg | Daily | $198.00 | ||
Conjugated estrogens/bazedoxifene | Duavee (Pfizer) | 0.45 mg/20 mg | Daily | $202.04 | |
Parathyroid Hormone Analogues | |||||
Teriparatide | Forteo (Eli Lilly) | 250 mcg/mL 2.4 mL pen |
SC | 20 mcg daily | $3,953.64 |
Abaloparatide | Tymlos (Radius Health) | 2,000 mcg/mL 1.56 mL pen |
80 mcg daily | $1,950.00 | |
Calcitonin-Salmon | |||||
Calcitonin-salmon | Generic | 200 IU/ actuation 3.7 mL | IN | 1 spray daily | $118.54 |
Miacalcin (Novartis) | 200 IU/mL | SC | 100 IU daily | $21,921.52 |
One-month supply unless otherwise specified.
AWP = average wholesale price; DR = delayed release; IN = intranasal; IV = intravenous; PO = oral; RANKL = receptor activator of nuclear factor kappa-B ligand; SC = subcutaneous.